問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

蔡育傑Tsai, Yu-Chieh
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

76Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡育傑

List

145Cases

2024-06-01 - 2027-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-04-01 - 2028-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-12-17 - 2030-08-23

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2031-07-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostate cancer

  • Test Drug

    Frozen Crystal Injection Injection Injection Lumps Lumps Lumps

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2020-07-22 - 2025-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-06-15 - 2022-10-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2022-05-02 - 2028-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-12-01 - 2033-05-05

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

2021-08-01 - 2028-01-30

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Test Drug

    膠囊劑

Participate Sites
6Sites

Recruiting6Sites

2019-01-24 - 2020-07-31

Phase II

Completed
Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TAS-120

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

1 5 6 7 8 9 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB